Swansea Innovations, 2nd Floor, Talbot Building, SA2 8PP
+44 (0)1792 606577

Seraticin (P100031)

Swansea researchers have been developing a potentially valuable treatment for fighting infections, including the MRSA. This technology, trademarked under the name SERATICIN® which has been in development for over ten years, is based on maggot secretions which have been used since ancient times to clean wounds. Work is establishing the definitive chemical structure and a method for its synthesis. SERATICIN® offers the prospect of a highly effectively antibacterial candidate in a format compatible with modern drug delivery modes. Given the effectiveness of and lack of side effects from the original treatment using live maggots, the prospects for success are particularly high.

A patent has been granted.

Inventors: Alyson Bexfield, Alison Bond, Edward Dudley, Russell Peter Newton, Yamni Nigam & Norman Arthur Ratcliffe